share_log

Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis

SEC announcement ·  Mar 20 14:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more